FDA Approves Nivolumab, First Immunotherapy for First-line Gastric Cancer

Published by W Butcher on

For the first time ever, the US Food and Drug Administration (FDA) has approved an immunotherapeutic agent for first-line treatment of gastric cancer. On April 16, the agency approved nivolumab (Opdivo; Bristol Myers Squibb) – in combination with certain types of chemotherapy – for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. 

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.